Stock on Focus: Corcept Therapeutics Incorporated (CORT)

Company Profile:

Corcept Therapeutics Incorporated, a pharmaceutical company, discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR). As of December 31, 2016, it had discovered three structurally distinct series of selective cortisol modulators, all of which share mifepristone’s affinity for GR but, unlike mifepristone, do not bind to the progesterone receptor. It is conducting two clinical trials of its selective cortisol modulator, CORT125134. One trial is investigating CORT125134 as a treatment for patients with Cushing syndrome. The second trial is investigating the combination of CORT125134 and nab-paclitaxel (Celgene Corporation’s Abraxane) to treat patients with solid-tumor cancers. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.

Recent News:

Corcept Therapeutics Incorporated (CORT) closed the Friday at final price of $17.89. CORT traded 2.37 million shares in last trading period. The average volume was noted at 1.53 million shares and its relative volume was seen at 1.54. The stock is currently showing healthy return of 7.71% throughout last week and witnessed Bullish return of 0.79% in one month period.

On Dec. 20, 2017, it was reporteed that Corcept Therapeutics Inc. (CORT) will replace Gigamon Inc. (GIMO) in the S&P SmallCap 600 effective prior to the open of trading on Wednesday, December 27.

 

Fundamental Analysis:

Ninestocks analyzes several different financial aspects: Growth, Profitability, solvency and efficiency.

Growth – Measures the growth of both the company’s income statement and cash flow.

@@@@@

Profitability – Measures the historical price movement of the stock.

@@@@@

Solvency – Measures the solvency of the company based on several ratios.

@@@@@

Efficiency – Measures the strength and historic growth of a company’s return on invested capital.

a

Conclusion:

CORT’s strengths can be seen in its strong profitability, strong solvency and robust efficiency compared with its peers. Its revenue and net income have increased over recent several years. Technical indicators signal the bullish signs, as there is a bullish cross in MACD and Stochastic Oscillator and RSI (14) stands at 55.29 with positive bias. We rate Corcept Therapeutics Incorporated (CORT) a STRONG BUY.

About the Author

has written 10074 stories on this site.

Copyright © 2012 Nine Stocks